NATH BIOGENES (INDIA)
|
NATH BIOGENES (INDIA) Last 5 Year Financial Ratios History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 21.91 | 20.31 | 20.85 | 18.43 | -35.46 |
| CEPS(Rs) | 23.99 | 22.32 | 22.56 | 20.01 | -33.84 |
| DPS(Rs) | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 |
| Book NAV/Share(Rs) | 358.06 | 339.08 | 320.94 | 301.61 | 285.16 |
| Tax Rate(%) | 10.09 | 4.89 | 4.68 | 3.19 | -6.23 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 11.82 | 13.72 | 15.02 | 16.25 | 13.37 |
| EBIT Margin(%) | 14.03 | 14.06 | 15.26 | 15.44 | -18.96 |
| Pre Tax Margin(%) | 10.40 | 11.12 | 12.50 | 12.00 | -22.79 |
| PAT Margin (%) | 9.35 | 10.58 | 11.91 | 11.62 | -24.21 |
| Cash Profit Margin (%) | 10.24 | 11.62 | 12.89 | 12.62 | -23.10 |
| Performance Ratios | |||||
| ROA(%) | 3.92 | 4.05 | 4.74 | 4.57 | -15.03 |
| ROE(%) | 6.28 | 6.15 | 6.70 | 6.28 | -22.48 |
| ROCE(%) | 7.88 | 6.90 | 7.26 | 7.09 | -14.84 |
| Asset Turnover(x) | 0.42 | 0.38 | 0.40 | 0.39 | 0.62 |
| Sales/Fixed Asset(x) | 1.61 | 1.32 | 1.22 | 1.12 | 1.62 |
| Working Capital/Sales(x) | 1.16 | 1.12 | 1.08 | 0.99 | 1.02 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.62 | 0.76 | 0.82 | 0.89 | 0.62 |
| Receivable days | 71.47 | 91.63 | 105.14 | 110.74 | 69.85 |
| Inventory Days | 323.33 | 284.23 | 240.40 | 259.30 | 195.06 |
| Payable days | -367.18 | -249.00 | -1,457.17 | 744.29 | 1,503.38 |
| Valuation Parameters | |||||
| PER(x) | 5.83 | 7.18 | 8.33 | 7.69 | - |
| PCE(x) | 5.32 | 6.53 | 7.70 | 7.08 | -6.31 |
| Price/Book(x) | 0.36 | 0.43 | 0.54 | 0.47 | 0.75 |
| Yield(%) | 1.57 | 1.37 | 1.15 | 1.41 | 0.94 |
| EV/Net Sales(x) | 0.69 | 0.85 | 1.09 | 1.12 | 1.78 |
| EV/Core EBITDA(x) | 5.05 | 5.69 | 7.18 | 6.79 | 12.65 |
| EV/EBIT(x) | 4.88 | 6.06 | 7.15 | 7.23 | -9.36 |
| EV/CE(x) | 0.37 | 0.41 | 0.50 | 0.50 | 0.78 |
| M Cap / Sales | 0.55 | 0.76 | 0.99 | 0.89 | 1.46 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 21.98 | 9.71 | 10.37 | 8.26 | 102.15 |
| Core EBITDA Growth(%) | 10.67 | 7.94 | 2.11 | 26.77 | 90.81 |
| EBIT Growth(%) | 21.71 | 1.09 | 9.13 | 188.13 | -430.58 |
| PAT Growth(%) | 7.85 | -2.57 | 13.16 | 151.96 | -673.70 |
| EPS Growth(%) | 7.85 | -2.57 | 13.11 | 151.98 | -583.10 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.20 | 0.19 | 0.18 | 0.18 | 0.17 |
| Current Ratio(x) | 1.97 | 1.89 | 2.18 | 2.40 | 2.41 |
| Quick Ratio(x) | 0.83 | 0.96 | 1.30 | 1.44 | 1.27 |
| Interest Cover(x) | 3.86 | 4.78 | 5.52 | 4.49 | -4.96 |
| Total Debt/Mcap(x) | 0.57 | 0.44 | 0.33 | 0.39 | 0.23 |
Compare Financial Ratios of peers of NATH BIOGENES (INDIA)
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| NATH BIOGENES (INDIA) | ₹284.7 Cr | -1.4% | -2% | -10.1% | Stock Analytics | |
| KAVERI SEED COMPANY | ₹4,146.3 Cr | 13.4% | 2.5% | -33.8% | Stock Analytics | |
| VENKYS (INDIA) | ₹2,327.2 Cr | 0.5% | 3.6% | 9.3% | Stock Analytics | |
| AVT NATURAL PRODUCTS | ₹1,410.3 Cr | 2.7% | 6.5% | 24.5% | Stock Analytics | |
| BOMBAY SUPER HYBRID SEEDS | ₹923.8 Cr | 2% | -1.2% | NA | Stock Analytics | |
| MANGALAM GLOBAL ENTERPRISE | ₹526.6 Cr | 0.8% | 9% | -0.1% | Stock Analytics | |
NATH BIOGENES (INDIA) Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| NATH BIOGENES (INDIA) | -1.4% |
-2% |
-10.1% |
| SENSEX | -0.5% |
-4.8% |
-11% |
You may also like the below Video Courses
